Assessment of the efficacy of copolymer-1 in the treatment of MS by quantitative MRI

Cohen, Jeffery A.; Grossman, R I; Jk, Udupa; Samarasekera, Supun; Miki, Y.; Hait, Himangsu; Grossman, M.; Constantinescu, CS; Kolson, DL; González‐Scarano, Francisco

doi:10.1016/0165-5728(95)98951-7

Cited by 6 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The results showed a reduction in relapse rate of 29% in the drug-treated group. There was no difference in progression to sustained disability in either the drug-or placebotreated group and a very limited MRI study did not show any treatment effect on total T2 lesion load or in the number of new enhancing lesions (79). All patients treated with glatiramer acetate developed antibodies suggesting there was no neutralizing effect (80).…”

Section: Glatiramer Acetatementioning

confidence: 99%

The management of multiple sclerosis: Current and future therapies

Stevenson¹,

Thompson²

1998

Drugs of Today

View full text Add to dashboard Cite

Management of the patient with multiple sclerosis (MS) encompasses a number of distinct, if overlapping, areas. They include anticipation and prevention of problems, symptom control, drug therapies aimed at reducing disease activity and finally, rehabilitation and service delivery. The recent advent of new immunosuppressant treatments for MS is extremely exciting. Beta-interferons (1a and 1b) are now licensed worldwide and glatiramer acetate (Copaxane ®) is in use in the United States. Many more drugs, including intravenous immunoglobulin, mitoxantrone, methotrexate and cladribine, are undergoing trials and some are showing promising results. Future therapies with monoclonal antibodies and adhesion molecules are also undergoing extensive research. Realistically, however, these new treatments aimed at reducing disease activity will have little impact on existing problems or the degree of disability. Consequently, much of the management of a patient with MS relates to control of the vast array of symptoms. These range from the obvious problems of weakness and spasticity, ataxia and sphincter disturbance, to less common but still important problems such as visual, cognitive, swallowing and respiratory difficulties. Some of the most common, and to the patient most disabling, symptoms are fatigue, thermal sensitivity and pain, areas often neglected by the physician in the face of more obvious physical needs. Much can be done for the patient in all areas. A combination of education, physiotherapy and drug therapy is usually required but occasionally there is a place for more invasive treatments such as intrathecal baclofen administration for severe spasticity or thalamic surgery for cerebellar tremor. A multidisciplinary team approach is essential in the overall management of the patient with MS,

show abstract

Section: Glatiramer Acetatementioning

confidence: 99%

The management of multiple sclerosis: Current and future therapies

Stevenson¹,

Thompson²

1998

Drugs of Today

View full text Add to dashboard Cite

show abstract

“…There was a trend, but no signi®cant proof for lessening progression. Only 27 patients in this study underwent serial gadolinium-enhanced cranial MRI scans, 24 and a bene®cial eect could not be demonstrated. Side eects noted with glatiramer acetate are mild and infrequent, and include injection site reaction, chest pain, asthenia, infection, pain, arthralgia, anxiety and hypertonia.…”

Section: Glatiramer Acetatementioning

confidence: 93%

Current immunotherapy in multiple sclerosis

Whitaker

1998

Immunol Cell Biol

View full text Add to dashboard Cite

Summary The underlying pathophysiology of multiple sclerosis is presumed to be autoimmune in nature. Attempts to ®nd an eective treatment for this common disease of the central nervous system have primarily focused on immune-mediated therapies, both immunosuppressive and immunomodulatory. The wide variety of immunological abnormalities detected in multiple sclerosis and its animal model, experimental allergic encephalomyelitis, has prompted the testing of a diverse array of drugs to be used for treatment. Recent successes in the treatment of relapsing-remitting multiple sclerosis with interferon b and glatiramer acetate have renewed interest in and raised expectations for the eective control of this neurological disorder. Improved methodology in clinical trials, the development of surrogate markers and the availability of novel therapies bode well for more rapid advances.

show abstract

“…Bisher lagen Befunde zum magnetresonanztomographischen Wirkprofil von Glatiramerazetat nur in sehr begrenztem Umfang vor [24,25]. Jüngst wurde über eine Reduktion von kontrastmittelaktiven Läsionen und Hirnatrophieentwicklung unter GLAT-Therapie berichtet [26].…”

Section: Das Magnetresonanztomographische Wirkprofilunclassified